ExeVir is a clinical-stage company developing antiviral therapies using its VHH technology platform to provide broad protection against viral infections, including coronaviruses. The platform builds on research led by Prof. Xavier Saelens and Prof. Nico Callewaert. ExeVir Bio is guided by a leadership team with extensive international experience in biotech and pharmaceutical development and a proven track record of advancing products to market.